Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Link to relevant study record(s)

Description of key information

After single oral application of 0.5, 5.3 or 51 mg sec-alkane sulfonate-sodium salt SAS - 14C via gavage to 3 groups of 6 male rats per group, blood levels reached a maximum about 2 to 6 hours after administration. Elimination from the blood was biphasic with biological half-lives of 11 and 65 hours. Up to 17 % of the administered radioactivity was exhaled as CO2; approximately 30 % was excreted via urine and about 45 % with faeces. In total more than 90 % of the applied radioactivity was excreted within the first 24 hours after application. Indications of bioaccumulation were not revealed as demonstrated by very low residual radioactivity (< 1 ppm) in organs after 7 days.

Dermal application of about 0.25 mg sec-alkane sulfonate-sodium salt SAS - 14C onto approximately 6 cm2 shaved back skin for 1.25 hours revealed maxima in blood levels about 2 to 6 hours p.a. Elimination half-life was in average about 41 hours (air approximately 15 %, urine approximately 18 %, faeces approximately 31 %). Most radioactivity was found in the bandage (approximately 35 %) whereas only about 2.2 % was detected in the treated skin 7 days p.a. The available data point to a low skin penetration potential of sec-alkane sulfonate-sodium salts SAS.

Key value for chemical safety assessment

Bioaccumulation potential:
no bioaccumulation potential
Absorption rate - dermal (%):

Additional information

Single oral or dermal administration of radiolabelled sec-alkane sulfonate-sodium salts SAS-C14 revealed that the kinetic behaviour is independent of the administered dose. After oral as well as after dermal exposure, highest blood levels occurred approximately 2 to 6 hours after application. Elimination was biphasic with half-lifes of about 11 and 65 hours after oral and approximately 41 hours after dermal exposure. In both cases more than 90% of the applied doses were eliminated within 24 hours. The available data point to a low skin penetration potential of sec-alkane sulfonates SAS. Indications of a bioaccumulative behaviour were not found. Residuals of less than 1 ppm of the administered dose were found in organs and tissues 7 days p.a.

Discussion on bioaccumulation potential result:

Experimental studies using radiolabelled sec-alkane sulfonate-sodium salts SAS have not revealed indications of a significant bioaccumulation potential.

Discussion on absorption rate:

Experimental studies using radiolabelled test material have not revealed indications that sec-alkane sulfonate-sodium salts SAS is significantly absorbed through skin after dermal treatment. This result is in line with data for ionic substances where percutaneous absorption is considered to be very low. A dermal penetration rate of approximately 1% for sec-alkane sulfonate-sodium salts SAS as for anionic substances in general is therefore considered scientifically justified.